KRAS and lung carcinoma: In contrast, Pten mutations were not observed to be concomitant with KrasG12D mutation but were found to co-occur with loss of Trp53. Analysis of human lung cancer samples confirmed the preference for loss of PTEN together with TP53 and co-occurrence of KRAS and STK11 mutations.